Total proctocolectomy and ileostomy were considered. Total proctocolectomy would have reduced the risk of recurrent CD, which would be difficult to manage given uncertainties about reinitiating immunomodulators or biologics in a patient with treated lymphoma. The patient believed she would not be able to manage a stoma due to debility from RA. Subtotal colectomy and ileorectal anastomosis was considered, but the concern was that this might worsen her perianal disease due to looser bowel movements. Pathology of the resected colon showed the ulcerated stricture, but no lymphoma or malignancy. Thirty-one lymph nodes were negative for malignancy. The patient is well, and not taking biologics and immunomodulators eight months postoperatively. Colonoscopy eight months postoperatively revealed a patch of mild ulceration at 50 cm from the anal verge. Biopsies were consistent with CD. There is no evidence of lymphoma recurrence.
DisCussion
The relationship between inflammatory bowel disease (IBD) and lymphoma is unclear. Previous population-based studies have suggested that male patients with CD may have an increased risk of developing lymphoma (1). Other research does not support this finding, showing only a marginal increase in risk for the development of lymphoma in CD, and no evidence for an increase in risk for ulcerative colitis (2) .
Medical management of IBD with immunomodulators (azathioprine or 6-mercaptopurine) is associated with an increased risk of developing lymphoma (3). Hepatosplenic T cell lymphoma is recognized to occur in a small number of patients taking tumour necrosis imAge of the month ©2014 Pulsus Group Inc. All rights reserved 
(CD30 immunohistochemistry, original magnification ×200). The cells were also immunoreactive for MUM1, BCL-2, BCL 6, p53, CD4, Ki67 (70%) and weakly for ALK1 (not shown)
factor (TNF)-alpha inhibitors, especially if concomitant immunomodulators are used (4). To our knowledge, the present case is the third report of ALCL of the colon. It is also the first reported case of ALCL occurring in a CD patient treated with a TNF-alpha inhibitor (infliximab) and concurrent immunomodulator (methotrexate). There have been two previously reported cases of colonic ALCL. One involved a patient with ulcerative colitis on no medications (5). The other was a patient with ileocolonic anastomosis for colonic adenocarcinoma (6) . It is unclear whether our patient developed ALCL due to CD, medications or both.
Our patient presented with laboratory and radiological findings suggestive of a typical CD flare. Had she been managed without endoscopy, her lymphoma would have been missed. This highlights the importance of considering endoscopy to confirm the clinical impression of active CD. A dilemma is the future management of her CD and RA should they become active. Our patient's infliximab and methotrexate were discontinued due to concern they were involved in the genesis of her lymphoma. Fortunately, her CD and RA have been quiescent. Should her CD or RA reactivate, it will be difficult to decide whether to restart TNF-alpha inhibitors or immunomodulators, given that these medications may increase the risk of lymphoma recurrence. Overall, it is unclear whether the development of ALCL in our patient was related to her medications, her CD or both. It is important to consider the risk of lymphoma when managing patients with IBD. 
